Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

208 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19: A structured summary of a study protocol for a randomised controlled trial.
Bosaeed M, Mahmoud E, Hussein M, Alharbi A, Alsaedy A, Alothman A, Aljeraisy M, Alqahtani H, Nashabat M, Almutairi B, Almaghaslah M, Aldibasi O, AlJohani S, Bouchama A, Arabi Y, Alaskar A. Bosaeed M, et al. Among authors: alqahtani h. Trials. 2020 Oct 31;21(1):904. doi: 10.1186/s13063-020-04825-x. Trials. 2020. PMID: 33129363 Free PMC article.
Multicentre randomised double-blinded placebo-controlled trial of favipiravir in adults with mild COVID-19.
Bosaeed M, Alharbi A, Hussein M, Abalkhail M, Sultana K, Musattat A, Alqahtani H, Alshamrani M, Mahmoud E, Alothman A, Alsaedy A, Aldibasi O, Alhagan K, Asiri AM, AlJohani S, Al-Jeraisy M, Alaskar A. Bosaeed M, et al. Among authors: alqahtani h. BMJ Open. 2021 Apr 14;11(4):e047495. doi: 10.1136/bmjopen-2020-047495. BMJ Open. 2021. PMID: 33853806 Free PMC article.
Favipiravir and Hydroxychloroquine Combination Therapy in Patients with Moderate to Severe COVID-19 (FACCT Trial): An Open-Label, Multicenter, Randomized, Controlled Trial.
Bosaeed M, Mahmoud E, Alharbi A, Altayib H, Albayat H, Alharbi F, Ghalilah K, Al Arfaj A, AlJishi J, Alarfaj A, Alqahtani H, Almutairi BM, Almaghaslah M, Alyahya NM, Bawazir A, AlEisa S, Alsaedy A, Bouchama A, Alharbi M, AlShamrani M, Al Johani S, Aljeraisy M, Alzahrani M, Althaqafi AO, Almarhabi H, Alotaibi A, Alqahtani N, Arabi YM, Aldibasi OS, Alaskar A. Bosaeed M, et al. Among authors: alqahtani h, alqahtani n. Infect Dis Ther. 2021 Dec;10(4):2291-2307. doi: 10.1007/s40121-021-00496-6. Epub 2021 Jul 28. Infect Dis Ther. 2021. PMID: 34319552 Free PMC article.
Clinical characteristics and risk factors of patients with severe COVID-19 in Riyadh, Saudi Arabia: A retrospective study.
Aleanizy FS, Alqahtani FY, Alanazi MS, Mohamed RAEH, Alrfaei BM, Alshehri MM, AlQahtani H, Shamlan G, Al-Maflehi N, Alrasheed MM, Alrashed A. Aleanizy FS, et al. Among authors: alqahtani h, alqahtani fy. J Infect Public Health. 2021 Sep;14(9):1133-1138. doi: 10.1016/j.jiph.2021.07.014. Epub 2021 Jul 28. J Infect Public Health. 2021. PMID: 34343963 Free PMC article.
Outcomes associated with tocilizumab with or without corticosteroid versus dexamethasone for treatment of patients with severe to critical COVID-19 pneumonia.
AlQahtani H, AlBilal S, Mahmoud E, Aldibasi O, Alharbi A, Shamas N, Alsaedy A, Owaidah K, Alqahtani FY, Aleanizy FS, Arishi H, Baharoon S, Bosaeed M. AlQahtani H, et al. Among authors: alqahtani fy. J Infect Public Health. 2022 Jan;15(1):36-41. doi: 10.1016/j.jiph.2021.11.017. Epub 2021 Nov 24. J Infect Public Health. 2022. PMID: 34883296 Free PMC article.
Efficacy of favipiravir in adults with mild COVID-19: a randomized, double-blind, multicentre, placebo-controlled clinical trial.
Bosaeed M, Alharbi A, Mahmoud E, Alrehily S, Bahlaq M, Gaifer Z, Alturkistani H, Alhagan K, Alshahrani S, Tolbah A, Musattat A, Alanazi M, Jaha R, Sultana K, Alqahtani H, Al Aamer K, Jaser S, Alsaedy A, Ahmad A, Abalkhail M, AlJohani S, Al Jeraisy M, Almaziad S, Albaalharith N, Alabdulkareem K, Alshowair A, Alharbi NK, Alrabiah F, Alshamrani M, Aldibasi O, Alaskar A. Bosaeed M, et al. Among authors: alqahtani h. Clin Microbiol Infect. 2022 Apr;28(4):602-608. doi: 10.1016/j.cmi.2021.12.026. Epub 2022 Jan 11. Clin Microbiol Infect. 2022. PMID: 35026375 Free PMC article. Clinical Trial.
Evaluation of ceftazidime/avibactam for treatment of carbapenemase-producing carbapenem-resistant Enterobacterales with OXA-48 and/or NDM genes with or without combination therapy.
Alqahtani H, Alghamdi A, Alobaidallah N, Alfayez A, Almousa R, Albagli R, Shamas N, Farahat F, Mahmoud E, Bosaeed M, Abanamy R. Alqahtani H, et al. JAC Antimicrob Resist. 2022 Oct 11;4(5):dlac104. doi: 10.1093/jacamr/dlac104. eCollection 2022 Oct. JAC Antimicrob Resist. 2022. PMID: 36237571 Free PMC article.
208 results